Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

A controlled trial of mitoxantrone in multiple sclerosis: serial MRI evaluation at one year.
The Relative Importance of Baseline Pain, Fatigue, Sleep and Physical Activity: Predicting Change in Depression in Adults with Multiple Sclerosis.
Pathological mechanisms in progressive multiple sclerosis.
Immunomodulatory drugs (natalizumab), worsening of multiple sclerosis, rebound effect and similitude.
Intellectual enrichment lessens the effect of brain atrophy on learning and memory in multiple sclerosis.
Autoantibody to MOG suggests two distinct clinical subtypes of NMOSD.
Pharmacogenetic study of long-term response to interferon-β treatment in multiple sclerosis.
Volumetric comparisons of supratentorial white matter hyperintensities on FLAIR MRI in patients with migraine and multiple sclerosis.
MRI outcomes with cladribine tablets for multiple sclerosis in the CLARITY study.
A 5-Year Follow-up of Rituximab Treatment in Patients With Neuromyelitis Optica Spectrum Disorder.
Reactive astrocytes form scar-like perivascular barriers to leukocytes during adaptive immune inflammation of the CNS.
The Stigma Scale for Chronic Illnesses 8-Item Version (SSCI-8): Development, Validation and Use Across Neurological Conditions.
Monomethyl fumarate promotes Nrf2-dependent neuroprotection in retinal ischemia-reperfusion.
Pharmacokinetic properties and metabolism of idebenone.
Human endogenous retroviruses and multiple sclerosis: innocent bystanders or disease determinants?
Glatiramer acetate treatment normalizes deregulated microRNA expression in relapsing remitting multiple sclerosis.
Immunologic monitoring during a phase 2a trial of the GNbAC1 antibody in patients with MS.
Binding of recombinant T cell receptor ligands (RTL) to antigen presenting cells prevents upregulation of CD11b and inhibits T cell activation and transfer of experimental autoimmune encephalomyelitis.
CD56(bright) natural killer cells and response to daclizumab HYP in relapsing-remitting MS.
Immunological Markers for PML Prediction in MS Patients Treated with Natalizumab.
The majority of CD1d-sulfatide-specific T cells in human blood use a semiinvariant Vδ1 TCR.
A Study of Orally Administered BGC20-0134 (Structured Lipid) in Patients With Relapsing Remitting Multiple Sclerosis (RRMS)
Epidemiology of Neuromyelitis Optica in the United States: A Multicenter AnalysisEpidemiology of NMO.
Toll-like receptor 2 and poly(ADP-ribose) polymerase 1 promote central nervous system neuroinflammation in progressive EAE.
[Intractable vomiting as first manifestation of neuromyelitis Optica.]

Pages